Free quiz
Health Needs Topic Hub

Dog Heart Health: Prevention, Monitoring, and Treatment Guide

Evidence-based hub for canine cardiovascular health — covering mitral valve disease, dilated cardiomyopathy, congestive heart failure, and breed-specific cardiac screening protocols.

9 min read

Breeds in this guide

Cavalier King Charles Spaniel Doberman Pinscher Boxer Dachshund Chihuahua

Heart Disease Affects More Dogs Than Most Owners Expect

Up to 90% of Cavalier King Charles Spaniels will develop mitral valve disease by age 10. Doberman Pinschers face a 58% lifetime risk of dilated cardiomyopathy — and sudden death can be the first symptom. Cardiovascular disease is the second leading cause of non-accidental death in dogs, yet both of these dominant conditions are progressive, breed-predisposed, and far more manageable when caught early through screening rather than after clinical signs emerge.

The Two Major Cardiac Diseases

Myxomatous Mitral Valve Disease (MMVD)

MMVD is the most common heart disease in dogs, affecting an estimated 10% of all dogs and up to 90% of Cavalier King Charles Spaniels over age 10. Myxomatous degeneration causes the mitral valve leaflets to thicken and lose apposition, creating a systolic murmur and progressive regurgitation.

Stages (ACVIM Consensus 2019):

  • Stage A: At-risk breed; no murmur — no treatment
  • Stage B1: Murmur present; no cardiac enlargement — no treatment
  • Stage B2: Murmur + cardiac enlargement — pimobendan indicated
  • Stage C: Congestive heart failure (CHF) — full medical management
  • Stage D: Refractory CHF — escalated treatment

Key resources:

Dilated Cardiomyopathy (DCM)

DCM is characterized by left ventricular dilation and systolic dysfunction. It is the primary cardiac disease of large and giant breeds: Doberman Pinscher, Irish Wolfhound, Great Dane, Boxer, and Cocker Spaniel. Dobermans are the highest-risk breed — up to 58% develop DCM, and sudden cardiac death can be the first sign.

Key resources:

Breed-Specific Cardiac Screening

Cavalier King Charles Spaniel

Annual cardiac auscultation from age 1. CKCS Health Scheme: if murmur-free at age 2.5 with both parents murmur-free at age 2.5, puppy is considered lower risk. Echocardiography from Stage B1 onward to track progression toward B2.

Doberman Pinscher

Annual Holter monitor (24-hour ECG) from age 3 to detect ventricular premature contractions (VPCs) — the arrhythmia that precedes clinical DCM and is associated with sudden death. Annual echocardiography from age 3–4.

Boxer

Annual ECG/Holter for arrhythmogenic right ventricular cardiomyopathy (ARVC / “Boxer cardiomyopathy”) — VPCs, syncope, sudden death. Echocardiography to assess right ventricular function.

Irish Wolfhound / Great Dane

Annual echocardiography from age 3; Holter monitoring if VPCs detected.

Key Cardiac Drugs

Pimobendan: the most important advance in canine cardiology. Positive inotrope + vasodilator. Initiated at Stage B2 (pre-clinical heart failure with enlargement) in MMVD, and at DCM diagnosis. The EPIC trial demonstrated that pimobendan at Stage B2 delays onset of CHF by 15 months on average.

ACE inhibitors (enalapril, benazepril): used from Stage C; reduce afterload and neurohormonal activation. Not as clearly beneficial at Stage B2 as pimobendan.

Furosemide / torsemide: loop diuretics for fluid management in CHF. Titrated to effect.

Spironolactone: aldosterone antagonist; added in CHF for cardioprotective effect.

Nutrition and Cardiac Health

The grain-free diet / DCM association (FDA investigation 2018–2022) created significant concern about taurine-deficient diets and DCM. The evidence remains incomplete but suggests certain grain-free, legume-heavy diets may impair taurine synthesis in some dogs. Current recommendations: avoid diets where legumes (peas, lentils) are in the top 4 ingredients for breeds predisposed to DCM.

Owner Monitoring Protocol

Heart disease in dogs is often progressive and clinically silent in early stages. Structured home monitoring is particularly valuable because early detection — before clinical signs of congestive heart failure appear — directly impacts treatment outcomes and survival time.

Daily resting respiratory rate (RRR): This is the single most important home monitoring tool for cardiac patients. Count your dog’s breaths per minute while it is resting or sleeping (one inhale + exhale = one breath). Normal resting rate is 15-30 breaths per minute.

  • Establish a baseline: record the resting respiratory rate daily for one week to determine your individual dog’s normal range.
  • Track trends: a persistent increase of more than 20% above baseline, or a resting rate consistently above 30 breaths per minute, may indicate early fluid accumulation in the lungs — the first sign of congestive heart failure.
  • For dogs diagnosed with heart disease (MMVD Stage B2 or DCM), daily RRR monitoring is recommended. The EPIC trial data demonstrated that an increase in resting respiratory rate was the most sensitive early indicator of decompensation into CHF.

Weekly assessments:

  • Exercise tolerance: note whether the dog tires more quickly than usual during walks, stops to rest during activities it previously completed easily, or is reluctant to climb stairs. Progressive exercise intolerance is a key early sign of cardiac compromise.
  • Cough monitoring: a soft cough after excitement or pulling on a leash can indicate left atrial enlargement compressing the mainstem bronchus — common in MMVD. A cough that worsens at night or when lying down suggests pulmonary edema.
  • Abdominal distension: right-sided heart failure can produce ascites (fluid in the abdomen). A progressively distended abdomen in a dog with known heart disease is an escalation trigger.

Breed-Specific Screening Timelines

Proactive screening in high-risk breeds catches disease during the preclinical phase, when intervention has the greatest impact:

  • Cavalier King Charles Spaniels: annual cardiac auscultation beginning at age 1. Echocardiography once a murmur is detected to stage disease progression. Given that up to 90% of this breed develops MMVD, screening is not optional — it is a core component of responsible ownership.
  • Doberman Pinschers: annual Holter monitor (24-hour ECG) and echocardiography starting at age 3. This breed can develop fatal ventricular arrhythmias before any echocardiographic changes are visible, making Holter monitoring essential. Sudden death without prior symptoms occurs in a meaningful percentage of affected dogs.
  • Boxers: annual ECG or Holter monitor from age 3-4 to screen for arrhythmogenic right ventricular cardiomyopathy. Syncope (fainting) during exercise is a red flag.
  • Great Danes and Irish Wolfhounds: annual echocardiography from age 3. Both breeds carry significant DCM risk, and their large body size means cardiac output demands are high.
  • Dachshunds and Chihuahuas: MMVD risk increases from middle age onward. Annual cardiac auscultation from age 5-6 is appropriate, with echocardiography upon murmur detection.
  • Cocker Spaniels: DCM risk, particularly in the American variety. Annual cardiac screening from age 5-6.

Escalation Triggers

Contact your veterinarian immediately if you observe:

  • Resting respiratory rate persistently above 40 breaths per minute — this strongly suggests congestive heart failure and requires urgent treatment
  • Sudden collapse, fainting (syncope), or episodes of weakness — particularly during exercise or excitement. In Doberman Pinschers and Boxers, syncope may indicate life-threatening ventricular arrhythmias
  • New cough that worsens at night or when lying down
  • Rapid-onset abdominal distension (ascites from right-sided heart failure or pericardial effusion)
  • Blue or purple discoloration of the gums or tongue (cyanosis) — indicates critically inadequate oxygenation
  • Sudden onset of labored breathing or open-mouth breathing at rest
  • Persistent loss of appetite combined with exercise intolerance in a dog with known heart disease

For dogs already on cardiac medications (pimobendan, furosemide, ACE inhibitors), do not adjust dosages without veterinary guidance. However, if CHF symptoms are worsening despite current treatment, a medication adjustment may be urgently needed.

Frequently Asked Questions

How do I measure my dog’s resting respiratory rate at home?

Count your dog’s breaths while it is resting calmly or sleeping — one full inhale plus exhale equals one breath. Count for 30 seconds and multiply by two, or count for a full 60 seconds for accuracy. Normal resting respiratory rate is 15-30 breaths per minute. Establish a baseline by recording the rate daily for one week, then monitor regularly. A persistent rate above 30 breaths per minute, or an increase of more than 20% above your dog’s established baseline, may indicate early fluid accumulation in the lungs and warrants veterinary evaluation. This is the single most important home monitoring tool for dogs with known heart disease.

Are grain-free diets dangerous for my dog’s heart?

The FDA investigation (2018-2022) identified a potential association between certain grain-free, legume-heavy diets and dilated cardiomyopathy (DCM), but the evidence remains incomplete and the mechanism is not fully established. The concern centers on diets where legumes (peas, lentils, chickpeas) are among the top ingredients, potentially impairing taurine synthesis in some dogs. Current veterinary consensus recommends avoiding diets with legumes in the top four ingredients for breeds already predisposed to DCM, such as Doberman Pinschers and Great Danes. See the grain-free DCM risk assessment for a detailed review.

What is pimobendan and why is it so important in canine cardiology?

Pimobendan is a positive inotrope and vasodilator that represents the most significant advance in canine heart disease management. The EPIC trial demonstrated that starting pimobendan at MMVD Stage B2 (before the dog develops congestive heart failure) delays the onset of heart failure by an average of 15 months. It strengthens cardiac contraction while reducing the workload on the heart. For dogs with mitral valve disease or DCM, pimobendan is typically the first medication prescribed once cardiac enlargement is confirmed on echocardiography.

Does my dog’s breed determine what kind of heart disease it will get?

Breed is the strongest predictor of cardiac disease type. Small breeds — Cavalier King Charles Spaniels, Dachshunds, Chihuahuas — overwhelmingly develop mitral valve disease, which involves degeneration of the heart valve. Large and giant breeds — Doberman Pinschers, Great Danes, Irish Wolfhounds — predominantly develop dilated cardiomyopathy, where the heart muscle weakens and the chambers enlarge. Knowing your breed’s cardiac risk profile determines the screening protocol and the age at which screening should begin.

Can heart disease in dogs be cured?

In most cases, canine heart disease is managed rather than cured. MMVD and DCM are progressive conditions where the goal of treatment is to delay progression, manage symptoms, and maintain quality of life for as long as possible. With appropriate medication (pimobendan, ACE inhibitors, diuretics), many dogs with congestive heart failure live comfortably for months to years after diagnosis. Surgical mitral valve repair is available at a small number of specialty centers and can be curative, but it is technically demanding, expensive, and not widely accessible.